Antibiotics
Cubicin granted marketing approval in Europe
Published in Anti-Infectives Week, February 20th, 2006
The marketing approval was granted in the 25 member states of the European Union, Iceland, Liechtenstein, and Norway. Under the approval, Cubicin is indicated for the treatment of complicated skin and soft-tissue infections caused by Gram-positive bacteria.
Cubicin is expected to become available in the United Kingdom and the Netherlands shortly, followed by additional European countries, in accordance with local legal regulations.
"The launch of Cubicin in Europe provides an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
Source: Anti-Infectives Week (2006-02-20)
More Articles from Anti-Infectives Week
- Antimicrobials
Epsilon-polylysine has antimicrobial activity against three common pathogens - Drug Resistance
Pair of studies offer new clues to combat antibiotic resistance - Infection Control
Response algorithm controls transmission of airborne-spread diseases - Toxic Shock Syndrome
Prophylactic antibiotics prevent toxic shock syndrome in burn patients - Tuberculosis Therapy
Acquired resistance and eradication of susceptible bacteria can occur concurrently - Adverse Drug Reaction
Antimicrobial agents can cause drug interactions in children treated for cancer - More from this issue of Anti-Infectives Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
